NewAmsterdam Pharma Company N.V. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
NewAmsterdam Pharma Company N.V. (NAMS) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 23.29 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-05
- NewAmsterdam Pharma Company N.V. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 24.32M shares, a 3.22% decline year-over-year.
- NewAmsterdam Pharma Company N.V. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 25.13M shares, a 12.56% increase year-over-year.
- NewAmsterdam Pharma Company N.V. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 22.33M shares, a 12.16% increase year-over-year.
- NewAmsterdam Pharma Company N.V. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 19.91M shares.
- NewAmsterdam Pharma Company N.V. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 23.84M shares, a 9.35% increase from fiscal 2024.
- NewAmsterdam Pharma Company N.V. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 21.80M shares, a 10.12% increase from fiscal 2023.
- NewAmsterdam Pharma Company N.V. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 19.80M shares, a 24.42% increase from fiscal 2022.
- NewAmsterdam Pharma Company N.V. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 15.91M shares, a 280.23% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|
| 2026-06-30 | 23.29M shares 10-Q · filed 2026-08-05 | |||
| 2026-03-31 | 24.32M shares 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | 23.84M shares 10-K · filed 2026-02-18 | |||
| 2025-09-30 | 25.09M shares 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | 25.54M shares 10-Q · filed 2026-08-05 | |||
| 2025-03-31 | 25.13M shares 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | 21.80M shares 10-K · filed 2026-02-18 | |||
| 2024-09-30 | 22.88M shares 10-Q · filed 2025-11-05 | |||
| 2024-06-30 | 22.48M shares 10-Q · filed 2025-08-06 | |||
| 2024-03-31 | 22.33M shares 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | 19.80M shares 10-K · filed 2026-02-18 | |||
| 2023-09-30 | 18.77M shares 10-Q · filed 2024-11-06 | |||
| 2023-06-30 | 17.98M shares 10-Q · filed 2024-08-07 | |||
| 2023-03-31 | 19.91M shares 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | 15.91M shares 10-K · filed 2025-02-26 | |||
| 2021-12-31 | 4.19M shares 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |